Phosphoglycerate dehydrogenase is dispensable for breast tumor maintenance and growth

Oncotarget

Volumn 4, Issue 12, 2013, Pages 2502-2511

  Chen, Jinyun ^a   Chung, Franklin ^a   Yang, G Guizhi ^a   Pu, Minying ^a   Gao, Hui ^a   Jiang, Wei ^a   Yin, Hong ^a   Capka, Vladimir ^a   Kasibhatla, Shailaja ^b   Laffitte, Bryan ^b   Jaeger, Savina ^a   Pagliarini, Raymond ^a   Chen, Yaoyu ^a   Zhou, Wenlai ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

Author keywords

Breast cancer cells; In vivo; PHGDH

Indexed keywords

GLYCINE; PHOSPHOGLYCERATE DEHYDROGENASE; SERINE;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CATALYSIS; CELL GROWTH; CELL PROLIFERATION; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; MCF-7 CELLS; MICE; PHOSPHOGLYCERATE DEHYDROGENASE; RNA, SMALL INTERFERING;

EID: 84891913582     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1540     Document Type: Article

References (27)

1. Hsu PP and Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008; 134(5):703-707.
2. Jones RG and Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes&development. 2009; 23(5):537-548.
3. Snell K. Enzymes of serine metabolism in normal, developing and neoplastic rat tissues. Advances in enzyme regulation. 1984; 22:325-400.
4. Achouri Y, Rider MH, Schaftingen EV and Robbi M. Cloning, sequencing and expression of rat liver 3-phosphoglycerate dehydrogenase. The Biochemical journal. 1997; 323 ( Pt 2):365-370.
5. Walsh DA and Sallach HJ. Purification and properties of chicken liver D-3-phosphoglycerate dehydrogenase. Biochemistry. 1965; 4(6):1076-1085.
6. Knox WE, Herzfeld A and Hudson J. Phosphoserine phosphatase distribution in normal and neoplastic rat tissues. Archives of biochemistry and biophysics. 1969; 132(2):397-403.
7. Lund K, Merrill DK and Guynn RW. The reactions of the phosphorylated pathway of L-serine biosynthesis: thermodynamic relationships in rabbit liver in vivo. Archives of biochemistry and biophysics. 1985; 237(1):186-196.
8. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, Sethumadhavan S, Woo HK, Jang HG, Jha AK, Chen WW, Barrett FG, Stransky N, Tsun ZY, Cowley GS, Barretina J, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 2011; 476(7360):346-350.
9. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen T, Sharfi H, Sasaki AT, Anastasiou D, Mullarky E, Vokes NI, Sasaki M, Beroukhim R, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nature genetics. 2011; 43(9):869-874.
10. Fan M, Pfeffer SR, Lynch HT, Cassidy P, Leachman S, Pfeffer LM and Kopelovich L. Altered transcriptome signature of phenotypically normal skin fibroblasts heterozygous for CDKN2A in familial melanoma: relevance to early intervention. Oncotarget. 2013; 4(1):128-141.
11. Ma L, Tao Y, Duran A, Llado V, Galvez A, Barger JF, Castilla EA, Chen J, Yajima T, Porollo A, Medvedovic M, Brill LM, Plas DR, Riedl SJ, Leitges M, Diaz-Meco MT, et al. Control of nutrient stress-induced metabolic reprogramming by PKCzeta in tumorigenesis. Cell. 2013; 152(3):599-611.
12. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. The international journal of biochemistry&cell biology. 2011; 43(7):969-980.
13. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL and Cantley LC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008; 452(7184):230-233.
14. Mazurek S, Boschek CB, Hugo F and Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Seminars in cancer biology. 2005; 15(4):300-308.
15. Macintyre AN and Rathmell JC. PKM2 and the tricky balance of growth and energy in cancer. Molecular cell. 2011; 42(6):713-714.
16. Lv L, Li D, Zhao D, Lin R, Chu Y, Zhang H, Zha Z, Liu Y, Li Z, Xu Y, Wang G, Huang Y, Xiong Y, Guan KL and Lei QY. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Molecular cell. 2011; 42(6):719-730.
17. Cortes-Cros M, Hemmerlin C, Ferretti S, Zhang J, Gounarides JS, Yin H, Muller A, Haberkorn A, Chene P, Sellers WR and Hofmann F. M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(2):489-494.
18. Walsh MJ, Brimacombe KR, Anastasiou D, Yu Y, Israelsen WJ, Hong BS, Tempel W, Dimov S, Veith H, Yang H, Kung C, Yen KE, Dang L, Salituro F, Auld DS, Park HW, et al. (2010). ML265: A potent PKM2 activator induces tetramerization and reduces tumor formation and size in a mouse xenograft model. Probe Reports from the NIH Molecular Libraries Program. (Bethesda (MD).
19. Network CGAR. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013; 499(7456):43-49.
20. Chaneton B, Hillmann P, Zheng L, Martin AC, Maddocks OD, Chokkathukalam A, Coyle JE, Jankevics A, Holding FP, Vousden KH, Frezza C, O'Reilly M and Gottlieb E. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature. 2012; 491(7424):458-462.
21. Kung C, Hixon J, Choe S, Marks K, Gross S, Murphy E, DeLaBarre B, Cianchetta G, Sethumadhavan S, Wang X, Yan S, Gao Y, Fang C, Wei W, Jiang F, Wang S, et al. Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chemistry&biology. 2012; 19(9):1187-1198.
22. Liu J, Guo S, Li Q, Yang L, Xia Z, Zhang L, Huang Z and Zhang N. Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1. Journal of neuro-oncology. 2013; 111(3):245-255.
23. Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, Gao X, Aldape K and Lu Z. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature. 2011; 480(7375):118-122.
24. Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, Jha AK, Smolen GA, Clasquin MF, Robey RB and Hay N. Hexokinase 2 Is Required for Tumor Initiation and Maintenance and Its Systemic Deletion Is Therapeutic in Mouse Models of Cancer. Cancer cell. 2013.
25. Debnath J, Muthuswamy SK and Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods. 2003; 30(3):256-268.
26. Chen Y, Chen J, Loo A, Jaeger S, Bagdasarian L, Yu J, Chung F, Korn J, Ruddy D, Guo R, McLaughlin ME, Feng F, Zhu P, Stegmeier F, Pagliarini R, Porter D, et al. Targeting HSF1 sensitizes cancer cells to HSP90 inhibition. Oncotarget. 2013.
27. Jin LH, Shao QJ, Luo W, Ye ZY, Li Q and Lin SC. Detection of point mutations of the Axin1 gene in colorectal cancers. International journal of cancer Journal international du cancer. 2003; 107(5):696-699.